| Identification | More | [Name]
Mirtazapine | [CAS]
85650-52-8 | [Synonyms]
1,2,3,4,10,14B-HEXAHYDRO-2-METHYLPYRAZINO[2,1-A]PYRIDO[2,3-C][2]BENZAZEPINE
MIRTAZANINE
MIRTAZAPINE
MIRTAZEPINE
ORG-3770
REMERON
(rs)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino-[2,1-a]pyrido[2,3-c][2]benzazepine
ZISPIN
Mirtazapin | [EINECS(EC#)]
288-060-6 | [Molecular Formula]
C17H19N3 | [MDL Number]
MFCD00865427 | [Molecular Weight]
265.35 | [MOL File]
85650-52-8.mol |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
22 | [Safety Statements ]
S22:Do not breathe dust .
S24/25:Avoid contact with skin and eyes . | [RIDADR ]
UN1230 - class 3 - PG 2 - Methanol, solution | [WGK Germany ]
3
| [RTECS ]
UQ4410250 | [HS Code ]
29339900 |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
An α2-Adrenergic blocker; analogue of Mianserin. Antidepressant. | [Uses]
Mirtazapine (Remeron, Avanza) is a potent tetracyclic antidepressant. Mirtazapine (Remeron, Avanza) used primarily in the treatment of depression. It is also sometimes used as a hypnotic, antiemetic, and appetite stimulant, and for the treatment of anxiet | [Definition]
ChEBI:Mirtazapine is a benzazepine and a tetracyclic antidepressant. It has a role as an alpha-adrenergic antagonist, a serotonergic antagonist, a histamine antagonist, an anxiolytic drug, a H1-receptor antagonist and a oneirogen. | [Brand name]
Remeron (Organon). | [General Description]
Mirtazapine is a tetracyclic antidepressant marketed under the trade names Remeron?, Avanza, or Zispin for treatment of depression.?This Certified Spiking Solution? is suitable for LC/MS or GC/MS applications in forensic analysis, clinical toxicology, or urine drug testing. | [Biological Activity]
Antidepressant agent; potent 5-HT 2 , 5-HT 3 and histamine H 1 receptor antagonist and moderately potent α 2 -adrenoceptor antagonist (pK i values are 8.05, ~ 8.1, 9.3 and 6.95 respectively). Enhances noradrenalin (NA) release in rat brain via inhibition of α 2 -adrenergic autoreceptors and displays only weak affinity for monoamine transporters (pK i values are 5.6, < 5 and < 5.1 for inhibition of NA, dopamine and 5-HT uptake respectively). Increases hippocampal NA and 5-HT levels in rats following systemic administration in vivo . | [Biochem/physiol Actions]
Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT1A mediated serotonergic signaling are increased. | [Clinical Use]
Antidepressant | [Veterinary Drugs and Treatments]
Currently, the only FDA approved indication for mirtazapine is
depression in humans. Reported veterinary uses include treatment
of chemotherapy-induced nausea and vomiting (CINV); anorexia
associated with renal failure (azotemia), congestive heart failure,
gastro-intestinal disorders, liver disease, or neoplasia. Other uses
suggested include stress induced diseases; insomnia; post-pyometra
symptoms; and post-operative inappetance. Studies have shown
that mirtazapine also alleviated sleep apnea in rats and humans.
There are case reports published in human literature of mirtazapine
use as treatment for non-mechanical vomiting after gastric
bypass, CINV, obsessive-compulsive disorder, nocioception
and chronic pain, migraine headache prophylaxis, anti-psychotic
induced akathisia, idiopathic nausea and vomiting, serotonin syndrome
induced nausea, anorexia, irritable bowel syndrome, resistant
hyperemesis gravidarum, and for the treatment of negative
symptoms of schizophrenia. Studies in rats have also shown that
mirtazapine significantly improves memory. | [Drug interactions]
Potentially hazardous interactions with other drugs
Alcohol: increased sedative effect.
Antidepressants: possibly increased risk of
serotonergic effects with fluoxetine, fluvoxamine or
venlafaxine; CNS excitation and hypertension with
MAOI and moclobemide - avoid.
Antimalarials: avoid with artemether and
lumefantrine and piperaquine with artenimol.
Methylthioninium: risk of CNS toxicity - avoid if
possible. | [Metabolism]
Extensively metabolised in the liver via CYP2D6,
CYP1A2, and CYP3A4. The major biotransformation
pathways are demethylation and oxidation followed by
glucuronide conjugation. The N-desmethyl metabolite is
pharmacologically active.
Elimination is via urine and faeces (15%). | [storage]
Store at 2-8°C |
|
|